Kavar Capital Partners Group LLC Sells 1,380 Shares of Edwards Lifesciences Co. (NYSE:EW)

Kavar Capital Partners Group LLC decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 12.7% during the 4th quarter, Holdings Channel reports. The firm owned 9,497 shares of the medical research company’s stock after selling 1,380 shares during the quarter. Kavar Capital Partners Group LLC’s holdings in Edwards Lifesciences were worth $703,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in EW. Bowman & Co S.C. raised its stake in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares during the last quarter. JFS Wealth Advisors LLC raised its position in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. Seascape Capital Management boosted its stake in Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Cooper Financial Group grew its holdings in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares during the last quarter. Finally, Martin Capital Advisors LLP lifted its position in Edwards Lifesciences by 0.7% during the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after buying an additional 186 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,000 shares of company stock worth $2,195,180. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 0.1 %

Shares of EW stock opened at $68.98 on Monday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $72.33 and a 200-day moving average of $70.36. The company has a market capitalization of $40.68 billion, a price-to-earnings ratio of 9.95, a P/E/G ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on EW shares. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Barclays increased their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Piper Sandler dropped their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.